7 results about "Galantamine" patented technology

The invention relates to a pharmaceutical composition comprising benzgalantamine and uses and methods for the preparation thereof. The present invention provides a pharmaceutical composition in the form of a tablet, said tablet comprising a tablet core, wherein said core comprises benzgalantamine (ALPHA-1062) or salt thereof, and an enteric coating, wherein said enteric coating is configured for dissolution at pH 5.5 and above. The pharmaceutical composition could be used in the treatment of a brain disease associated with cognitive impairment and / or with a cholinergic deficit. The invention further provides a method for preparing the pharmaceutical composition.

The application belongs to the technical field of biological medicine, and relates to a bipyridine compound, a preparation method thereof and application of the bipyridine compound in preparation of an AChE inhibitor. A chemical structural formula of the bipyridine compound is provided. The bipyridine compound provided by the application has AChE inhibitory activity, and the AChE inhibitory activity of the bipyridine compound is significantly higher than that of an existing clinical drug (such as galantamine), thereby providing a drug with better effect for treatment of Alzheimer's disease.

The invention provides a composition containing a phosphodiesterase 5 inhibitor (PDE5 inhibitor) and an acetylcholin esterase inhibitor (AChEI) for preventing or treating neurodegenerative diseases and a use method of the composition. Wherein the PDE5 inhibitor is selected from the group consisting of mironafil, sildenafil, vardenafil, tadalafil, udenafil, dabigatafil, avanafil, and pharmaceutically acceptable salts, solvates, hydrates and mixtures thereof; and the AchEI is selected from the group consisting of donepezil, rivastigmine, galanthamine, poison hyacinth alkali, tacrine, metriofonate, phenylserine, tolserine, eosin, huperzine A and huperzine B, galangin, anacardol, donepezine-AP2238, donepezil-tacrine, tacrine-ferulic acid hybrids, tacrine-hydroxyquinoline, ladotegil, an indenyl derivative thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable salt thereof. Pharmaceutically acceptable salts, solvates, hydrates, and mixtures; and the neurodegenerative disease is dementia, Parkinson's Disease (PD), Alzheimer's Disease (AD), Huntington's Disease (HD), or Multiple Sclerosis (MS).

Compositions and methods are described for improving brain health and cognitive function and for preventing and treating Alzheimer's disease and other age-related dementia diseases and conditions for intake as a dietary or nutritional supplement, for example, as a powdered drink mix. Compositions for providing an energy source to the brain during exercise are also described. The composition includes a source of choline, a source of magnesium, at least one taurine-containing composition, a source of ashwagandha root, and phosphatidylserine. The source of choline can be alpha-glycerylphosphorylcholine or citicoline and the source of magnesium can be magnesium-L-threonate or magnesium glycinate. The composition can further include at least one of oleic acid, oleanolic acid, ursolic acid, curcumin, piperine, galantamine, huperzine-A, a source of vitamin B5, L-tyrosine, and beta-hydroxybutyrate.

Disclosed are pharmaceutical compositions comprising azelastine or a pharmaceutically acceptable salt of azelastine and a therapeutically active ingredient of donepezil or rivastigmine or galantamine or a pharmaceutically acceptable salt thereof. Also disclosed are methods of using the pharmaceutical compositions to treat patients with mental disorders, behavioral disorders, cognitive disorders.

A method of effectively reducing the pharmaceutical load of galantamine relative to oral administration of galantamine or a method of effectively administering galantamine in a subject in need of galantamine therapy for the treatment of mild to moderate dementia of the Alzheimer's type, the methods including orally administering a dosage form of benzgalantamine gluconate according to the following dosage regime: administering a starting dosage of 5 mg benzgalantamine gluconate, twice daily, for a minimum of four weeks.

This invention discloses a galantamine nasal spray and its preparation method. The galantamine nasal spray is prepared from raw materials comprising the following components: galantamine or galantamine salt, viscosity modifier, pH adjuster, chelating agent, absorption enhancer, osmotic pressure regulator, preservative, and water, wherein the viscosity modifier is polyvinylpyrrolidone. This galantamine nasal spray has suitable viscosity, reasonable osmotic pressure and pH range, good flight stability, and a small spray area and plume angle, which can effectively improve the deposition rate of galantamine in the nasal olfactory region and effectively enhance the naso-brain drug delivery efficiency, thereby improving its therapeutic effect on Alzheimer's disease.